Dorsey Wright & Associates Purchases New Position in DBV Technologies S.A. $DBVT

Dorsey Wright & Associates purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 102,550 shares of the company’s stock, valued at approximately $2,142,000.

Several other hedge funds have also bought and sold shares of the stock. Allworth Financial LP acquired a new stake in shares of DBV Technologies during the 4th quarter worth approximately $32,000. Royal Bank of Canada acquired a new position in shares of DBV Technologies in the 4th quarter valued at $34,000. GAMMA Investing LLC lifted its stake in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC boosted its holdings in DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares in the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in DBV Technologies during the fourth quarter worth $115,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a report on Monday, June 29th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. Citizens Jmp raised their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Finally, Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $14.70 on Friday. The business’s 50 day moving average price is $17.14 and its 200 day moving average price is $19.48. The company has a market cap of $870.39 million, a price-to-earnings ratio of -4.19 and a beta of -0.95. DBV Technologies S.A. has a one year low of $8.51 and a one year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 122.92%. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.03 million. On average, analysts predict that DBV Technologies S.A. will post -0.38 EPS for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.